title: [Results of treatment with 2-chlorodeoxyadenosine in refractory or relapsed Langerhans cell histiocytosis. Study of 9 patients].
abstract: BACKGROUND
  To analyse the results of the treatment with 2-chlorodeoxyadenosine (2CdA) in 9 patients with refractory or relapsed Langerhans cell histiocytosis (LCH) tracted in 8 Spanish hospitals between 1993 and 1999.
  
  
  METHODS
  In the 9 patients the following data were recorded: age, sex, organ involvement by LCH, first treatment and response, dose, number of cycles and schedule of administration 2CdA, response to 2CdA treatment, toxicity, disease-free survival (DFS) and overall survival (OS).
  
  
  RESULTS
  Median age was 25 years (range, 6-63). All patients had multiorganic involvement by LCH, with severe organ dysfunction in 4. 2CdA was administered as second line treatment in 7 cases and as third line in 2. The 2CdA dose was 0.1 mg/kg per day during 5 days in the majority of patients, and interval between cycles was 4 weeks. In 2 cases a complete remission (CR) was achieved and 4 cases attained a partial remission (PR) (overall response rate 66%). The main toxicity was hematologic, with neutropenia grade > 2 in 5 cases and thrombocytopenia > 2 in 5. Four patients had infections, with fatal evolution in one of them. After a median follow-up of 8 months (range 2-17), 2 patients remained in CR (12 months both), 4 in PR (range 2-12 months) and one had active disease (17 months). The other two died due to progressive disease and Aspergillus spp. sepsis, respectively. The actuarial probabilities of DFS and OS were 58% (95% CI, 38-78%) and 71% (95% CI, 54-88%), respectively.
  
  
  CONCLUSIONS
  2CdA is an active drug for patients with refractory or relapsed LCH, and its main toxicity is myelosuppression. The usefulness of 2CdA, isolated or in combination with other drugs, in patients with refractory or relapsed LCH must be assessed in controlled studies.
authors.affiliation: Hospital Universitari Germans Trias i Pujol. Badalona. Barcelona.
authors.forename: J
authors.initials: J
authors.lastname: Grau
authors.forename: J M
authors.initials: JM
authors.lastname: Ribera
authors.forename: M
authors.initials: M
authors.lastname: Tormo
authors.forename: J M
authors.initials: JM
authors.lastname: Indiano
authors.forename: J
authors.initials: J
authors.lastname: Vercher
authors.forename: V
authors.initials: V
authors.lastname: Sandoval
authors.forename: G
authors.initials: G
authors.lastname: Ramírez
authors.forename: A
authors.initials: A
authors.lastname: Sastre
authors.forename: E
authors.initials: E
authors.lastname: Flores
authors.forename: J
authors.initials: J
authors.lastname: García-Conde
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D017338:Cladribine / Q000627:therapeutic use*; D005260:Female; D006646:Histiocytosis, Langerhans-Cell / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012008:Recurrence
chemical_list: D007166:Immunosuppressive Agents; D017338:Cladribine